<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997087</url>
  </required_header>
  <id_info>
    <org_study_id>JGS-001</org_study_id>
    <nct_id>NCT00997087</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder</brief_title>
  <acronym>OCD</acronym>
  <official_title>Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parkway Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parkway Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of flumazenil in the outpatient
      treatment of Obsessive Compulsive Disorder (OCD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study completed and data was inconclusive.
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by Adverse Events, Changes in physical exam, laboratory values.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Sugar Pill, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Flumazenil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumazenil</intervention_name>
    <description>Sublingual daily</description>
    <arm_group_label>Sugar Pill, Placebo</arm_group_label>
    <arm_group_label>Flumazenil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and provide written informed consent.

          -  Age 19-60, inclusive.

          -  Diagnosis documented according to DSM-IV of OCD.

          -  Exhibits moderate to severe OCD symptoms and a minimum score of 16 or greater -YBOCS
             at screening.

          -  Willing and able to discontinue current medications taken for the treatment of OCD.

          -  Able to attend and participate in all study visits.

          -  Agree to continue if in current psychosocial therapy throughout the remainder of the
             study.

          -  If female and of child-bearing potential, willing to use an acceptable method of birth
             control for the duration of the study.

          -  If male, willing to use barrier method of birth control or had previous vasectomy.

        Exclusion Criteria:

          -  Have other DSM-IV Axis I diagnoses.

          -  Pregnant as confirmed by urine analysis, or lactating, or unwilling to comply with use
             of contraception.

          -  Unwilling or unable to washout (discontinue) from prohibited medications such as
             antidepressants (See Appendix 2).

          -  Depression symptoms with a score of 15 or greater on the MADRS at screening.

          -  Current suicidal ideation or plan within the last 30 days.

          -  Have a medical condition which, in the opinion of the investigator, makes study
             participation unsafe or noncompliant.

          -  Abnormal physical exam or laboratory values which, in the opinion of the investigator,
             makes study participation unsafe or may require introduction of concomitant
             medications during the course of the study.

          -  Benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15
             days of potential flumazenil treatment: patients must not be habituated to
             benzodiazepines and must provide a urine sample that is negative for benzodiazepines,
             must not be taking supra-therapeutic doses of zolpidem (AmbienTM) or zaleplon
             (SonataTM ). (See Appendix 2).

          -  Patients who are taking Phenobarbital for a documented seizure disorder can be
             admitted. Patients with a seizure disorder being managed with clonazepam (KlonopinTM )
             or other benzodiazepine cannot participate, patients must not be taking TCA, lithium,
             methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors, bupropion HCL,
             and cyclosporine. (See Appendix 2).

          -  Previously treated with flumazenil for OCD.

          -  AIDS as determined by self-report.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James G Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkway Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James G. Sullivan, MD</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parkway Medical Center</investigator_affiliation>
    <investigator_full_name>James G.Sullivan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 10, 2018</submitted>
    <returned>May 11, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

